Silo Pharma Updates Business Address to Sarasota, FL
Ticker: SILO · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, address-change
TL;DR
**Silo Pharma just moved its office, no big deal for the stock.**
AI Summary
Silo Pharma, Inc. filed an 8-K on January 9, 2024, to update its business address from 560 Sylvan Ave, Suite 3160, Englewood Cliffs, NJ 07632 to 677 N. Washington Boulevard, Sarasota, FL 34236. This change is a routine administrative update and does not indicate any significant operational shifts or financial events. For investors, this simply means the company's physical location has moved, which typically has no direct impact on the stock's value or the company's core business operations.
Why It Matters
This filing is a routine administrative update, informing the public of Silo Pharma's new business address. It does not signal any operational changes or financial events that would directly impact the company's stock price or business strategy.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative, reporting a change of business address, which carries minimal risk to investors.
Analyst Insight
Smart investors would recognize this as a routine administrative update with no material impact on Silo Pharma's valuation or business prospects, thus requiring no immediate action based on this filing alone.
Key Players & Entities
- Silo Pharma, Inc. (company) — the registrant filing the 8-K
- 677 N. Washington Boulevard, Sarasota, FL 34236 (address) — Silo Pharma's new principal executive office address
- 560 Sylvan Ave, Suite 3160, Englewood Cliffs, NJ 07632 (address) — Silo Pharma's former principal executive office address
- January 9, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the primary purpose of Silo Pharma, Inc.'s 8-K filing on January 9, 2024?
The primary purpose of Silo Pharma, Inc.'s 8-K filing on January 9, 2024, is to report a change in its principal executive offices' business address from 560 Sylvan Ave, Suite 3160, Englewood Cliffs, NJ 07632 to 677 N. Washington Boulevard, Sarasota, FL 34236.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 9, 2024, which is the date the change of address became effective.
What was Silo Pharma, Inc.'s former business address?
Silo Pharma, Inc.'s former business address was 560 Sylvan Ave, Suite 3160, Englewood Cliffs, NJ 07632.
What is Silo Pharma, Inc.'s new business address as reported in the filing?
Silo Pharma, Inc.'s new business address, as reported in the filing, is 677 N. Washington Boulevard, Sarasota, FL 34236.
Does this 8-K filing indicate any changes in Silo Pharma, Inc.'s operations or financial status?
No, this 8-K filing is solely for the purpose of reporting a change in the company's business address and does not indicate any changes in Silo Pharma, Inc.'s operations, financial status, or strategic direction.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-01-09 16:30:11
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
- $1 million — ogram authorizing the purchase of up to $1 million of the Company's common stock until Mar
Filing Documents
- ea191279-8k_silopharma.htm (8-K) — 25KB
- 0001213900-24-002314.txt ( ) — 192KB
- silo-20240109.xsd (EX-101.SCH) — 3KB
- silo-20240109_lab.xml (EX-101.LAB) — 33KB
- silo-20240109_pre.xml (EX-101.PRE) — 22KB
- ea191279-8k_silopharma_htm.xml (XML) — 3KB
01 – Other Events
Item 8.01 – Other Events On January 9, 2024, the Board of Directors of Silo Pharma, Inc. (the "Company") approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1 million of the Company's common stock until March 31, 2024.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: January 9, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer -2-